- Home
- JHS vs BDTX Comparison
JHS vs BDTX Comparison
Compare JHS & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHS
- BDTX
- Stock Information
- Founded
- JHS 1973
- BDTX 2014
- Country
- JHS United States
- BDTX United States
- Employees
- JHS N/A
- BDTX N/A
- Industry
- JHS Finance Companies
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JHS Finance
- BDTX Health Care
- Exchange
- JHS Nasdaq
- BDTX Nasdaq
- Market Cap
- JHS 131.4M
- BDTX 132.5M
- IPO Year
- JHS N/A
- BDTX 2020
- Fundamental
- Price
- JHS $11.21
- BDTX $2.87
- Analyst Decision
- JHS
- BDTX Strong Buy
- Analyst Count
- JHS 0
- BDTX 6
- Target Price
- JHS N/A
- BDTX $14.83
- AVG Volume (30 Days)
- JHS 32.8K
- BDTX 1.2M
- Earning Date
- JHS 01-01-0001
- BDTX 08-05-2025
- Dividend Yield
- JHS 3.96%
- BDTX N/A
- EPS Growth
- JHS N/A
- BDTX N/A
- EPS
- JHS 0.02
- BDTX 0.09
- Revenue
- JHS N/A
- BDTX $70,000,000.00
- Revenue This Year
- JHS N/A
- BDTX N/A
- Revenue Next Year
- JHS N/A
- BDTX N/A
- P/E Ratio
- JHS $553.50
- BDTX $32.58
- Revenue Growth
- JHS N/A
- BDTX N/A
- 52 Week Low
- JHS $9.76
- BDTX $1.20
- 52 Week High
- JHS $11.25
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- JHS 49.06
- BDTX 68.91
- Support Level
- JHS $11.24
- BDTX $2.43
- Resistance Level
- JHS $11.30
- BDTX $2.72
- Average True Range (ATR)
- JHS 0.08
- BDTX 0.18
- MACD
- JHS 0.01
- BDTX 0.02
- Stochastic Oscillator
- JHS 35.14
- BDTX 99.31
About JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.